[Correspondence] Moxidectin combination therapies for lymphatic filariasis—36-month follow-up

Lymphatic filariasis is a mosquito-borne parasitic disease that causes disfiguring, and often disabling, limb lymphoedema and hydroceles. WHO's Global Programme to Eliminate Lymphatic Filariasis has reduced the number of individuals requiring mass drug administration for this disease from approximately 1·3 billion in 72 countries to 657 million in 39 countries. Of these, 206 million live in Africa, where lymphatic filariasis is usually co-endemic with onchocerciasis and where mass drug administration with ivermectin is used as preventative chemotherapy for both diseases.